Latest news with #Recce
Hans India
13 hours ago
- Entertainment
- Hans India
Promising start fizzles into predictable crime drama
Rating: 2.25/5 The web series Viraatapalem - PC Meena Reporting, starring Abhignya Vuthaluru and directed by Poluru Krishna, opens with a gripping premise but gradually loses steam, devolving into a formulaic and unconvincing crime drama. Set in the fictional town of Viraatapalem during the early 1990s, the story revolves around a chilling mystery — brides being killed on their wedding day. Villagers believe a curse is behind the deaths, halting weddings for years. Enter Meena, a determined young police officer posted in the town who takes the investigation into her own hands. In a dramatic move, Meena decides to get married herself to bait the killer. What follows is a series of episodes aimed at unmasking the truth behind the so-called curse. Despite a strong setup, the series falters after the initial episodes. The pacing dips, with later episodes feeling stretched and lacking in suspense. The absence of impactful cliffhangers, a hallmark of compelling crime thrillers, makes the narrative feel monotonous. Forced twists and weak character motivations further dampen the experience, particularly the plotline involving Meena's decision to marry, which feels unnatural and contrived. Performance-wise, Abhignya Vuthaluru holds her own and manages to engage viewers despite the uninspired screenplay. Surabhi Prabhavati also performs well in a significant role, but the rest of the supporting cast fails to leave a mark. On the technical front, the series features decent cinematography but lacks polish in production design. The dialogues are effective, and editing is crisp, but the overall execution is inconsistent. Director Poluru Krishna, who earlier delivered the hit Recce, does not replicate that success here. To add to its woes, Viraatapalem has been caught in controversy, with ETV Win accusing Zee5 of lifting its concept from their show Constable Kanakam. Viraatapalem - PC Meena Reporting starts strong but ultimately disappoints due to predictable storytelling, weak writing, and a lack of genuine thrills. Apart from a decent climax twist, the show struggles to leave a lasting impression.
Web Release
22-06-2025
- Entertainment
- Web Release
ZEE5 Global Drops the Gripping Trailer of ‘Viraatapalem: PC Meena Reporting', A Telugu Supernatural Thriller Premiering June 27
ZEE5 Global, the world's largest streaming platform for South Asian content, is all set to present its newest Telugu original series, 'Viraatapalem: PC Meena Reporting', a gripping supernatural thriller set against the hauntingly rural backdrop of Andhra Pradesh. Starring Abhignya Vuthaluru and Charan Lakkaraju and directed by Krishna Poluru, the series premieres on June 27. With eerie folklore, buried secrets, and a fearless investigation at its heart, the series promises an edge-of-your-seat, binge-worthy experience. The official trailer of the series was launched by actor Naveen Chandra, setting the tone for the suspense and intrigue that lies ahead. Link – Set in the 1980s, in the remote and fear-stricken village of Viraatapalem, a chilling curse silences celebrations, every bride dies mysteriously on her wedding day. No marriage has taken place for over a decade. The village is frozen in fear; its population reduced to only the very young and the very old. When a bold police constable (Abhignya Vuthaluru) is posted to the town, she refuses to accept the curse as truth. Teaming up with a reformed convict, she begins to pull at the threads of a mystery the village would rather keep buried. One woman: One village: A thousand secrets. And in Viraatapalem, some of those secrets are dying to stay hidden. Director Krishna Poluru shared, 'After Recce, I'm thrilled to collaborate with ZEE5 Global once again. 'Viraatapalem: PC Meena Reporting' is set in a village where a chilling curse has stopped weddings for over a decade, every bride dies mysteriously on her wedding day. That belief has turned into fear, and fear into silence. This series is about breaking that silence. We've built a world that feels real, eerie, and emotionally grounded, where one woman dares to ask the question, everyone is afraid of.' Producer KV Sriram, South Indian Screens shared: 'After the success of Recce, it feels great to join hands with ZEE5 Global once again for 'Viraatapalem: PC Meena Reporting'. This story stood out to me right from the beginning; it's haunting, layered, and deeply rooted in the kind of fears many communities quietly carry. As someone who has spent years creating stories for television and playing characters myself, this project gave me a chance to explore something more atmospheric and grounded. I'm proud of the world we've built with this series: mysterious, tense, and emotionally real, and I can't wait for audiences to experience it.' Abhignya Vuthaluru said, 'Being part of this project was intense and fulfilling. The role demanded sensitivity, strength, and vulnerability especially in a world that dismisses facts in favour of fear. Shooting in the village, surrounded by real locations and real people, gave the entire experience a rawness, audiences I am sure will like it.' With superstition, suspense, and a powerful message at its core, 'Viraatapalem: PC Meena Reporting' is not just a supernatural thriller, it's a battle between fear and truth, unfolding in the most unexpected of places. Don't miss 'Viraatapalem: PC Meena Reporting' streaming only on ZEE5 Global from June 27th
Hans India
19-06-2025
- Entertainment
- Hans India
Naveen Chandra Unveils Gripping Trailer of ZEE5's ‘Viraatapalem: PC Meena Reporting'
India's leading OTT platform, ZEE5, renowned for its engaging Telugu web series, is back with a brand-new thriller titled 'Viraatapalem: PC Meena Reporting', headlined by the talented Abhignya Vuthaluru. Directed by Poluru Krishna and produced by Sriram under the banner South Indian Screens, the series is set for its grand premiere on June 27. Ahead of the release, the makers unveiled the official trailer in Hyderabad, with popular actor Naveen Chandra doing the honors and extending his best wishes to the team. Set in the 1980s, 'Viraatapalem' delves into the eerie mystery of young brides who die under suspicious circumstances soon after marriage. The story follows PC Meena, a newly transferred constable, as she investigates a web of superstitions and secrets that shroud the village. Watch the trailer here: 🔗 Viraatapalem Trailer – Telugu 🔗 Press Meet Live The series also stars Charan Lakkaraju, Lavanya Sahukara, Ramaraju, Gowtham Raju, and Satish in key roles. The story was penned by Divya Thejaswi Pera, screenplay by Vikram Kumar Kandimalla, cinematography by Mahesh K Swaroop, editing by Farooq Hundekar, and background score by Rohit Kumar. Naveen Chandra shared, 'The poster caught my attention immediately. Having loved 'Recce', I was intrigued to know it's by the same director. Abhignya seems perfect for the role, and I'm confident this series will create a buzz. I'll binge-watch it on June 27, and I urge everyone to do the same.' Lead actress Abhignya said, 'Portraying a police constable tackling village superstitions is a unique and powerful role. Thank you to Divya for the script, and to Krishna garu and Sriram garu for believing in me.' Producer Sriram added, 'This story haunted me after the first narration. Abhignya's excitement convinced me she was right for the part. Krishna garu came on board despite his packed schedule, and I thank everyone who worked hard to make this possible.' Director Krishna said, 'After the success of 'Recce', I am thrilled to bring another compelling story with 'Viraatapalem'. I hope audiences enjoy it just as much.' ZEE5 Content Head Sai Tej revealed plans to expand the story into a franchise, with PC Meena taking on new missions in upcoming seasons. 'The series is family-friendly and binge-worthy, with a climax that will surprise everyone.' With strong performances, a gripping premise, and high production values, 'Viraatapalem: PC Meena Reporting' promises to be a must-watch thriller when it premieres exclusively on ZEE5, June 27. Don't miss it!
Yahoo
27-02-2025
- Business
- Yahoo
Recce Pharmaceuticals Granted Japanese Patent for RECCE® Anti-Infectives
SYDNEY, Feb. 27, 2025 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q), (Recce or the Company) the Company developing a new class of synthetic anti-infectives, today announced it was granted a Family 4 patent by the Japan Patent Office for its anti-infectives, with expiry in 2041. 'We are encouraged by the Japan Patent Office's formal recognition of Recce's new class of anti-infectives,' said James Graham, Chief Executive Officer of Recce Pharmaceuticals. 'Global patent protection underscores our commitment to addressing critical unmet medical needs with innovative therapies. We are well-positioned to deliver meaningful solutions for patients worldwide.' The Japan Patent claims relate to RECCE® 327 (R327) and RECCE® 529 (R529), including: Process for preparation of RECCE® anti-infectives Use of R327/R529 for the treatment of disease, particularly the treatment of bacterial infections, viral infections, and more Specifically, further validating RECCE® anti-infectives from studies in acute bacterial skin and skin structure infections (ABSSSI), diabetic foot infections (DFI), burn wounds, lung infections (i.e., ventilator-associated pneumonia/hospital-acquired pneumonia), urinary tract infections, gonorrhoea, influenza, and SARS-CoV2 Administration by oral, inhalation, transdermal delivery, or by injection (into the bloodstream, intramuscular, and/or intravenous) Administration may also be applied as an aerosol, gel, topical foam or ointment (or impregnated into a dressing for application to skin or mucous membranes for transdermal or transmucosal delivery) This is the fourth Family 4 patent, alongside Australia, Canada, and Israel, with further Patent Cooperation Treaty Country (PCT) submissions in respective stages of review/allowed. Japan is the third largest pharmaceutical market in the world,1 with a share of approximately 5% of the global pharmaceutical market.2 The antibiotic resistance market in Japan is expected to reach a projected revenue of $411.3 million by 2030. The Japanese antibiotic resistance market expects a compound annual growth rate of 6.1% from 2024 to 2030.3 About Recce Pharmaceuticals LtdRecce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q) is developing a New Class of Synthetic Anti-Infectives designed to address the urgent global health problems of antibiotic-resistant superbugs. Recce's anti-infective pipeline includes three patented, broad-spectrum, synthetic polymer anti-infectives: RECCE® 327 (R327) as an intravenous and topical therapy that is being developed for the treatment of serious and potentially life-threatening infections due to Gram-positive and Gram-negative bacteria, including their superbug forms; RECCE® 435 (R435) as an orally administered therapy for bacterial infections; and RECCE® 529 (R529) for viral infections. Through their multi-layered mechanisms of action, Recce's anti-infectives have the potential to overcome the processes utilised by bacteria and viruses to overcome resistance – a current challenge facing existing antibiotics. The World Health Organization (WHO) added R327, R435, and R529 to its list of antibacterial products in clinical development for priority pathogens, recognising Recce's efforts to combat antimicrobial resistance. The FDA granted R327 Qualified Infectious Disease Product designation under the Generating Antibiotic Initiatives Now (GAIN) Act, providing Fast Track Designation and 10 years of market exclusivity post approval. R327 is also included on The Pew Charitable Trusts' Global New Antibiotics in Development Pipeline as the sole synthetic polymer and sepsis drug candidate in development. Recce wholly owns its automated manufacturing, supporting current clinical trials. Recce's anti-infective pipeline aims to address synergistic, unmet medical needs by leveraging its unique technologies. Corporate ContactJames GrahamRecce Pharmaceuticals Ltd+61 (02) 9256 Media & Investor Relations (AU)Andrew GeddesCityPR+61 (02) 9267 4511ageddes@ Media (USA)Michael FitzhughLifeSci Communicationsmfitzhugh@ Investor Relations (USA & EU)Guillaume van RenterghemLifeSci Advisorsgvanrenterghem@ 1 3 in to access your portfolio
Yahoo
19-02-2025
- Business
- Yahoo
Recce Pharmaceuticals Reports Positive Data from Phase II Trial of RECCE® 327 Gel in Acute Bacterial Skin and Skin Structure Infections, Supporting Accelerated Commercialization Pathway
Phase II trial assessed the efficacy and safety of RECCE® 327 topical gel in patients with acute bacterial skin and skin structure infections (ABSSSI), including those with diabetic foot infections (DFI) Study objectives exceeded, with a 93% primary efficacy endpoint achieved for R327G over 14 days of treatment Data confirms the approach for the approved registrational Phase 3 DFI study in Indonesia, where efficacy can be confirmed earlier in the trial through interim analysis and read-out expected in 2025 Study to progress to registrational Phase 3 trial in Australia for ABSSSI and DFI Trial results reinforce the unprecedented efficacy of Recce's synthetic technology, now in late-stage clinical trials, facilitated by an innovative regulatory strategy, supporting an accelerated commercialization pathway into 2026 SYDNEY, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q), (Recce or the Company), the Company developing a new class of synthetic anti-infectives, today announced positive data from a Phase II trial evaluating RECCE® 327 Topical Gel (R327G) for the treatment of acute bacterial skin and skin structure infections (ABSSSI). 'These impressive results underscore the potential of our topical gel to meet critical unmet medical needs in infection treatment, said James Graham, CEO of Recce Pharmaceuticals. 'As we advance towards registrational Phase 3 trials in Indonesia and Australia, we are encouraged by the rapid efficacy and strong safety outcomes demonstrated in this study. The global ABSSSI treatment market is a substantial commercial opportunity, valued at $7.3B in 2018 and expected to reach $26B by 2032, at a CAGR of 9.5% between 2019 and 2032. Going forward with our clinical programs gives us great confidence in addressing ABSSSI.' Alan Dunton, MD, Director & Chief Medical Advisor of Recce Pharmaceuticals, added, 'Our robust dataset, from pre-clinical, clinical, and TGA special access scheme use cases, gives us confidence in the potential of our topical gel. These results reflect the broad-spectrum nature and rapid onset of the effect of R327G, which positions us well for the upcoming Phase 3 trials in Indonesia and Australia. Importantly, Recce has also demonstrated that its R327 anti-infective compounds are effective in vitro against diverse species of bacteria, including over 500 clinical isolates, many of which were previously considered drug-resistant.' The Phase II trial successfully demonstrated R327G achieving a 93% primary efficacy endpoint over 14 days, meeting all study endpoints. After 7 days of treatment, 86% of patients (25 out of 29) treated with R327G had a successful clinical response. At 14 days of treatment, 93% of patients (27 out of 29) achieved a primary efficacy endpoint. R327G demonstrated to be safe and well tolerated, with no serious adverse events (SAE) reported, achieving all endpoints. The study enrolled 30 patients, with 29 included in the final data analysis. One patient was withdrawn due to pre-existing pain at the wound site that was deemed unrelated to R327G. Driven by the high response rates in this study, experts have determined the Company's current registrational Phase 3 study for diabetic foot infections (DFI) can meet a statistically significant positive endpoint after completing approximately 100 patients compared to the study baseline of 300 patients. The Indonesian Drug and Food Regulatory Authority (Badan POM) approved protocol has a built-in interim analysis. The Company anticipates completing this data set by the end of the year. This Phase II study achieved all primary and secondary endpoints as an open-label clinical trial evaluating the safety, tolerability, efficacy, and plasma pharmacokinetics of R327G when applied directly to the infected area. The trial included both men and women with a minimum age of 18 years old and no maximum age limit. The data received from this trial aligns with the US Food and Drug Administration's (FDA) increased demand for novel broad-spectrum antibiotics (such as R327G) to address antimicrobial resistance (AMR). ABSSSIs are a significant healthcare concern, encompassing indications such as DFI, necrotizing fasciitis, and post-operative wound infections. There are no ABSSSI placebo-controlled studies as international regulators deem withholding appropriate treatment of patient infections unethical. The trial used FDA-accepted diagnostic tools for assessing the severity of patient wounds, including the Lipsky Clinical Resolution of Infection Scale and/or the Bates Jensen Wound Assessment tool. The study's investigators used these methods to evaluate wound healing and subsequently rated patients as either cured or improved. Both assessments (cured/improved) demonstrate that wound healing has been observed, with cured meaning a complete clinical response and improved demonstrating partial wound healing with the potential of a cure beyond the 14-day timeframe. About Recce Pharmaceuticals LtdRecce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q) is developing a New Class of Synthetic Anti-Infectives designed to address the urgent global health problems of antibiotic-resistant superbugs. Recce's anti-infective pipeline includes three patented, broad-spectrum, synthetic polymer anti-infectives: RECCE® 327 (R327) as an intravenous and topical therapy that is being developed for the treatment of serious and potentially life-threatening infections due to Gram-positive and Gram-negative bacteria, including their superbug forms; RECCE® 435 (R435) as an orally administered therapy for bacterial infections; and RECCE® 529 (R529) for viral infections. Through their multi-layered mechanisms of action, Recce's anti-infectives have the potential to overcome the processes utilised by bacteria and viruses to overcome resistance – a current challenge facing existing antibiotics. The World Health Organization (WHO) added R327, R435, and R529 to its list of antibacterial products in clinical development for priority pathogens, recognising Recce's efforts to combat antimicrobial resistance. The FDA granted R327 Qualified Infectious Disease Product designation under the Generating Antibiotic Initiatives Now (GAIN) Act, providing Fast Track Designation and 10 years of market exclusivity post approval. R327 is also included on The Pew Charitable Trusts' Global New Antibiotics in Development Pipeline as the sole synthetic polymer and sepsis drug candidate in development. Recce wholly owns its automated manufacturing, supporting current clinical trials. Recce's anti-infective pipeline aims to address synergistic, unmet medical needs by leveraging its unique technologies. Corporate ContactJames GrahamRecce Pharmaceuticals Ltd+61 (02) 9256 Media & Investor Relations (AU)Andrew GeddesCityPR+61 (02) 9267 4511ageddes@ Media (USA)Michael FitzhughLifeSci Communicationsmfitzhugh@ Investor Relations (USA & EU)Guillame van RenterghemLifeSci Advisorsgvanrenterghem@
